Author

Leda Mannent

DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

Leda Mannent  et al.

DUPILUMAB NORMALIZES EXPRESSION OF GENES ASSOCIATED WITH TYPE 2 INFLAMMATION IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
DUPILUMAB NORMALIZES EXPRESSION OF GENES ASSOCIATED WITH TYPE 2 INFLAMMATION IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS

Leda Mannent  et al.

THE GENE EXPRESSION SIGNATURE MODULATED BY DUPILUMAB IS HIGHLY CORRELATED WITH EOSINOPHILIC ESOPHAGITIS HISTOLOGICAL SEVERITY
THE GENE EXPRESSION SIGNATURE MODULATED BY DUPILUMAB IS HIGHLY CORRELATED WITH EOSINOPHILIC ESOPHAGITIS HISTOLOGICAL SEVERITY

Leda Mannent  et al.

DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY
DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY

Leda Mannent  et al.

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Leda Mannent  et al.

DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS
DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS

Leda Mannent  et al.

Item 1 - 6 / 6
1